CM336 Injection

BIOLOGICAL4 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China, Shandong First Medical University, Keymed Biosciences Co.Ltd

Conditions

Autoimmune Bullous DiseaseAutoimmune CytopeniaAutoimmune Hemolytic AnemiaEvans SyndromeImmune Thrombocytopenia (ITP)Multiple Myeloma (MM)Treatment

Phase 1

A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia

RecruitingNCT07175493

Keymed Biosciences Co.LtdAutoimmune Cytopenia, Autoimmune Hemolytic Anemia, Evans Syndrome +1

Start: 2025-11-18End: 2028-11-18Target: 158Updated: 2025-12-17

Phase 2

An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia

RecruitingNCT06799611

Institute of Hematology & Blood Diseases Hospital, ChinaImmune Thrombocytopenia (ITP), Treatment

Start: 2025-03-03End: 2027-01-31Target: 20Updated: 2025-03-13

A Study to Evaluate CM336 in Adults With Autoimmune Bullous Disease

RecruitingNCT06900010

Shandong First Medical UniversityAutoimmune Bullous Disease

Start: 2025-04-22End: 2028-01-01Target: 30Updated: 2026-04-06

Phase 3

Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients

Not yet recruitingNCT07181239

Keymed Biosciences Co.LtdMultiple Myeloma (MM)

Start: 2025-09-30End: 2030-04-30Target: 280Updated: 2025-09-18